About ViGenCell
ViGenCell is a company based in Seoul (South Korea) founded in 2013 was acquired by Boryung Pharmaceutical in August 2017. The company has 63 employees as of December 31, 2024. ViGenCell operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Seoul, South Korea
- Employees 63 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Vigencell, Inc.
-
Annual Revenue
$15.69 K (USD)-91.87as on Dec 31, 2025
-
Net Profit
-$11.29 M (USD)-16.08as on Dec 31, 2025
-
EBITDA
-$7.93 M (USD)26.82as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
63
as on Dec 31, 2024
-
Acquired by
Boryung Pharmaceutical
(Aug 10, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ViGenCell
ViGenCell is a publicly listed company on the KRX with ticker symbol 308080 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of ViGenCell
Detailed funding history for ViGenCell
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in ViGenCell
ViGenCell has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boryung Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Finished formulations and APIs are developed for diverse disease areas.
|
Locked | Locked | Locked |
Investor details for ViGenCell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ViGenCell
Investment portfolio details for ViGenCell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ViGenCell
Detailed financials for ViGenCell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vigencell Comparisons
Peer comparison for ViGenCell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ViGenCell
ViGenCell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of ViGenCell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vigencell
Complete news archive for ViGenCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViGenCell
ViGenCell was founded in 2013.
ViGenCell is headquartered in Seoul, South Korea.
Kim Tae-gyu is the current CEO of ViGenCell.
As of Dec 31, 2024, the latest employee count at ViGenCell is 63.
Annual revenue of ViGenCell is $15.69K as on Dec 31, 2025.
ViGenCell provides therapeutics solution for tumor based on immunological cells. It provides its propriety immunocytochemistry technology to improve the immunity of patients while tumors surgery, drug therapy, and radiotherapy. The leading candidate of the company are ViTier (CTL), ViRager ( γδT ), ViMedier (CBMS) involve in NK T cell lymphoma, acute bone marrow, Blood cancer, glioblastoma, solid cancer, graft-versus-host disease, and others, are in phase 1 and pre-clinical stage.
ViGenCell's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Yes, ViGenCell is publicly traded on KRX under the ticker symbol 308080.
ViGenCell has 1 investor. Key investors include Boryung Pharmaceutical.
The ticker symbol of ViGenCell is 308080 on KRX.